Weight Loss Injections in India: The 2026 Guide

The phrase covers two very different things, and conflating them is how people get hurt.

The real category is GLP-1 receptor agonists (and one dual GIP/GLP-1 agonist). These are hormone-based medicines that reduce appetite and slow stomach emptying. They are approved by regulators, studied in large randomised trials, and prescription-only.

The other category — “fat-dissolving”, lipolytic or mesotherapy injections offered at salons and some clinics — is not weight-loss treatment. Those are marketed for small areas of localised fat, have no evidence for meaningful body-weight reduction, and are frequently administered by people unqualified to manage a complication. If someone offers you a weight-loss injection without a prescription and without a medical history, that is the category you are being sold.

Four medicines, in practice:

• Tirzepatide (Mounjaro) — once weekly, acts on two receptors (GIP and GLP-1). The most effective option on average, and now India's top-selling drug by value.
• Semaglutide 2.4 mg (Wegovy) — once weekly, licensed specifically for weight management.
• Semaglutide (Ozempic) — once weekly, licensed for type 2 diabetes and capped at 2.0 mg, so weight-loss use is off-label.
• Liraglutide (Saxenda) — a daily injection, the oldest of the group and the least effective on average.

Since semaglutide's Indian patent expired on 20 March 2026, more than 40 generic versions have launched, which is what changed the economics of the entire category.

From the major trials, all alongside lifestyle support:

• Tirzepatide — about 21% of body weight at the 15 mg dose over 72 weeks (SURMOUNT-1).
• Semaglutide 2.4 mg — about 15% over 68 weeks (STEP 1).
• Liraglutide 3.0 mg — about 8% over 56 weeks (SCALE).

Treat these as averages with wide spread, not as promises. A minority of people respond poorly to any of them. And the trial figures come with structured lifestyle support attached — the injection alone is not what produced those numbers.

The 2026 generic launches reset this. Generic semaglutide is reported at roughly ₹1,300–₹4,200 per month, and branded Wegovy was cut by up to 48% in response. Tirzepatide remains patent-protected and sits substantially higher.

One thing worth being clear-eyed about: the medicine is not the only cost. Consultations, lab work and dose escalation all factor in, and a programme that quotes only the drug price is quoting you half the number. See the comparison table below.

Broadly, treatment is considered at a BMI of 27 or above with a weight-related condition (type 2 diabetes, hypertension, dyslipidaemia, sleep apnoea, fatty liver, PCOS), or at a BMI of 30 or above on its own.

For Indians those thresholds arguably sit lower. Asian populations carry more visceral fat and more metabolic risk at the same BMI, which is why Indian and Asia-Pacific guidance uses 23 for overweight and 25 for obesity rather than the Western 25 and 30. If you are judging yourself against a Western BMI chart, you may be underestimating your risk — our BMI calculator uses the Indian cutoffs.

Contraindications matter more than eligibility. These medicines are not for people with a personal or family history of medullary thyroid carcinoma or MEN 2, not for use in pregnancy, and need care in anyone with a history of pancreatitis or gallbladder disease.

This is the part that gets lost in the before-and-after framing. In the SELECT trial, semaglutide reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and existing cardiovascular disease but no diabetes.

There is also evidence across this drug class for improvement in blood sugar, blood pressure, liver fat and sleep apnoea. For a lot of patients those are the outcomes that actually matter — the weight is the mechanism, not the goal.

Side effects. Mostly digestive — nausea, vomiting, diarrhoea, constipation — worst in the first weeks and after each dose increase. Serious but uncommon risks include pancreatitis and gallbladder disease. All of this class carries a boxed warning for thyroid C-cell tumours based on rodent studies.

Muscle loss. A meaningful share of the weight lost is lean mass unless you deliberately protect it with protein and resistance training. Losing 20% of your body weight and a large fraction of your muscle is not the outcome you wanted.

Regain after stopping. Well documented, and the single most under-discussed fact in this category. Appetite returns when the drug stops. Obesity behaves like a chronic condition, so treatment plans should be built around maintenance from day one rather than an exit date.

Cost over time. Monthly, ongoing, and largely out of pocket in India.

Roughly, and subject to a clinician who has actually seen your bloods: tirzepatide if maximum effect is the priority and budget allows; generic semaglutide if cost is the binding constraint; Wegovy if you want the weight-management licence with branded supply; liraglutide rarely, given a daily injection for less effect.

The more useful reframe: the injection is the easy decision. What determines whether you keep the result is the protein, the training, the follow-up and the maintenance plan — which is why we do not sell the medicine on its own.